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Background: Ovarian hyperstimulation syndrome (OHSS), is characterized by marked ovarian enlargement and
acute third space fluid sequestration that almost always develops after hCG administration or in early pregnancy.
OHSS is similar to vascular leak syndrome (VLS), which may be attributable to the massive increase in systemic
inflammatory cytokines. In the present pilot exploratory case series, we sought to evaluate interleukin (IL)-2 and
suppressor of cytokine signaling (SOCS)-1 expressions in the peripheral blood mononuclear cells (PBMCs) of
patients suffering from severe ovarian hypertimulation syndrome (OHSS), and to examine whether their expressions
differ when compared to PBMCs originated from normal early pregnant women (without OHSS).
Methods: Interleukin-2 and SOCS-1 mRNA expressions were examined in PBMCs of 5 women who were hospitalized
due to severe OHSS (OHSS group) and 5 women with early IVF pregnancies and without OHSS (control group).
Results: Interleukin-2 mRNA levels in PBMCs were significantly higher in the OHSS as compared to the control groups.
Moreover, while SOCS-1 mRNA levels were non-significantly lower, the ratio between IL-2 and SOCS-1 mRNA levels was
significantly higher in the OHSS, as compared to the control group.
Conclusions: The inflammatory response to hCG, leading to dysregulation of Il-2 expression and SOCS activation,
might be the culprit of OHSS. Additional large prospective studies are required to elucidate the effect of hCG on patients’
inherited inflammatory cascades, which may help discriminating those at risk to develop severe OHSS from those who
are not.
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Ovarian hyperstimulation syndrome (OHSS) is a serious
complication of ovulation induction, almost always pre-
sents either after human chorionic gonadotropin (hCG)
administration in susceptible patients or during early
pregnancy. Its cardinal features are marked ovarian en-
largement and an increase in capillary permeability, with
the consequent acute third-space fluid sequestration and
its related morbidity [1,2]. Many factors and mediators* Correspondence: raoul.orvieto@sheba.health.gov.il
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unless otherwise stated.have been proposed as the intermediate, released by go-
nadotropin hyperstimulated ovaries at ovulation, which
causes the increase in capillary permeability. However,
despite many years of clinical experience, the patho-
physiology of OHSS is still poorly understood [3].
Interleukin-2 (IL-2), which is produced and secreted
by T-helper cells, serves as a central regulator or medi-
ator of the immune response. When administered to hu-
man subjects, IL-2 elicited multiple toxic side effects,
including “vascular leak syndrome” (VLS), which resem-
bles OHSS. As a consequent of the similarity between
VLS and OHSS, we have suggested that the hyperstimu-
lated human ovaries may contain IL-2 which, in turn,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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acteristic of OHSS [4].
In the last decades, several evidences have accumu-
lated, suggesting that cytokines stimulation leads to the
induction of suppressor of cytokine signaling (SOCS)
proteins, which are part of a negative feedback loop,
inhibiting cytokines signal transduction that initially
led to their production [5]. These regulatory proteins are
rapidly transcribed following intracellular Janus kinase-
signal transducer and activator of transcription (JAK-STAT)
activation, a cascade that governs biological functions,
including reproductive processes and cytokine-induced
immunological responses [6]. The SOCS family consists of
8 members that are able to antagonize STAT activation and
have an important role in cytokines’ balance that determine
the profile of T-helper type 1 (Th1)- and Th2-mediated
immune responses [7]. Of interest is the SOCS-1 protein,
that was demonstrated to be regulated by IL-2 [8], and
was also shown to be capable of inhibiting signaling initi-
ated by IL-2 [9].
Inspired by the hypothesis that SOCS-1 might modu-
late the negative effect of hCG on IL-2 production in
OHSS patients, we designed the present pilot explora-
tory case series, aimed to evaluate the expression of IL-2
and its suppressor, SOCS-1, in the PBMCs of patients suf-
fering from severe OHSS, and to examine whether their
expressions differ when compared to PBMCs originated
from normal early pregnant women (without OHSS).
Methods
Patients
The study population consisted of patients admitted to
our gynecology ward, during a 6 months period, due to
severe OHSS following an in-vitro fertilization (IVF)
treatment. Severe OHSS was defined according to Golan
et al. [10] and Navot et al. [1] criteria, while early and
late OHSS were defined according to Lyons et al. [11]:
3–7 days and 12–17 days following HCG ovulation trig-
gering, respectively. For the purpose of the study, in
addition to the routine follow-up and treatment, blood
was drawn from each patient on day 2 of hospitalization,
for PBMCs isolation.
The control group consisted of women who have been
treated in our IVF unit and conceived. It is our unit pol-
icy to measure serum hCG on 13–14 days after embryo
transfer (which is performed 3 or 2 days after oocytes re-
trieval, respectively). If the hCG result reveals a positive
pregnancy test (serum hCG levels ≥10 IU/L) a second
hCG measurement is performed 2–3 days later. On the
day of their second serum hCG measurement, blood was
drawn from each patient for PBMCs isolation. The con-
trol patients were chosen arbitrarily, from among pa-
tients who conceived during the study period and gave
their signed informed consent.The study required no modification of patients routine
follow-up or treatment. Informed consent was obtained
from all patients before participation in the study, and the
study was approved by the institutional Clinical Research
Committee, The Sheba Medical Center.
Peripheral blood mononuclear cells isolation (PBMCs)
Peripheral blood was collected into EDTA tubes. PBMCs
were isolated by gradient centrifugation at 2300 RPM for
30 minutes (brake off ) using Lymphoprep (Axis-Shield,
Oslo, Norway), according to the instructions from the
manufacturer. Cells were washed with phosphate-buffered
saline (PBS).
Total RNA extraction and reverse transcription
Total RNA isolation was performed using the RNeasy
Micro Kit (Qiagen, Valencia, CA) according to the man-
ufacturer’s instructions. The RNA quality was assessed
using a NanoDrop® ND-1000 Spectrophotometer. RNA
was transcribed to generate cDNA using qScript™ cDNA
Synthesis Kit (Quanta BioSciences) with optimized blend
of random hexamers and oligo (dT) primers according
to the manufacturer’s instructions.
Real-time quantitative PCR
Quantification of the mRNA messages coding for SOCS1,
IL-2 (gene of interest) and GAPDH (control housekeeping
gene) was performed using StepOnePlus™System (Applied
Biosystems). Quantitative PCR was performed in a total
reaction volume of 20 μl and runs were performed in
triplicate. Each 20 μl reaction mix contained 10 μl of a
PerfeCTa SYBR Green FastMix (Quanta BioSciences), 0.5-
10 pmol of each forward and reverse primer, 2 μl cDNA
(made from 0.5 μg RNA) and nuclease-free water to make
up the reaction volume. The primers used for real time
PCR were as follows:
GAPDH_F: 5′-GTA TTG GGC GCC TGG TCA-3′
GAPDH_R: 5′-AGG GGT CAT TGA TGG CAA CA-3′
IL-2_F: 5′-TCA AAC CTC TGG AGG AAG TGC T-3′
IL-2_R: 5′-CAT GAATGT TGT TTC AGATCC CTT-3′
SOCS-1_F: 5′-GCG ACTACC TGA GCT CCT TCC-3′
SOCS-1_R: 5′-CCA CAT GGT TCC AGG CAA GTA-3′
SYBR green I, a dye which binds to the minor groove
of double-stranded DNA (dsDNA) was used as the
method of detection. During the various stages of PCR,
different intensities of fluorescence signals were de-
tected, depending on the amount of dsDNA present. On
completion of the PCR, all PCR products formed were
melted to attain a melting curve profile, which enabled
the specificity of the reaction to be determined (Figure 1).
The melting curve analysis resulted in single product-
specific melting temperatures: 87.4°C (GADPH), 89.7°C
Figure 1 Amplification time for fluorescence detection and melting curve of PCR product. A: Melting curve (heat dissociation) analyses for
IL-2 gene expression. One PCR product peak at 78°C visible for the target PCR. The negative control shows no visible PCR product. B: Melting
curve of PCR product for SOCS-1 gene. The real time PCR specificity was determined by the dissociation temperature of PCR products. The single
peak at 84°C corresponded to the specific PCR product of SOCS-1 gene. C–D: Quantification of IL-2 (C) and SOCS-1(D) genes, in OHSS patients
compared to control. Subsequently the ΔCT for each sample was determined using the equation ΔCT = CTtarget gene – CThousekeeping gene.
ΔCT = CT (IL-2) – CT (GAPDH) ΔCT = CT (SOCS-1) – CT (GAPDH).
Orvieto et al. Journal of Ovarian Research 2014, 7:106 Page 3 of 6
http://www.ovarianresearch.com/content/7/1/106(SOCS1) and 89.7°C (IL2). No primer primer–dimer for-
mations were generated during the applied 40 real-time
PCR amplification cycles. Gene expression levels were
calculated by measuring the threshold cycle (CT), an
arbitrarily placed threshold which ensures the PCR is in
the exponential phase of amplification. The CT is re-
versely related to the amount of target molecules in
the reaction. The comparative CT method is used to
calculate the expression level of the gene of interest rela-
tive to a reference sample. In this study the analysis was
performed using DataAssist™ Software 3.01 (Applied
Biosystems).
Statistical analysis
The results are expressed as means ± standard errors
(SE) and medians + ranges. Differences in variables
between the two groups were statistically analyzed
with Student’s t-test and Wilcoxon rank-sum test, as
appropriate. P values of 0.05 or less were considered
significant.
Results
During the study period, 5 women were hospitalized at
early gestation and comprised our study group (OHSS
group). The control group consisted of 5 women with
normal early IVF pregnancies and without OHSS.
The demographic and clinical characteristics of the pa-
tients are presented in Table 1. Maternal age, parity,
body mass index and cause of infertility were similaramong both groups. As expected, the peak estradiol
levels on day of hCG administration (9292 ± 2464 pmol/L
vs 4167 ± 2730 pmol/L, p < 0.02; respectively) and the
number of oocytes retrieved (15.8 ± 2.3 vs 7.8 ± 3.9, p <
0.002; respectively) were significantly higher in the OHSS
as compared to the control group.
All the 5 women in our study group conceived via
IVF treatments and were hospitalized with late OHSS,
occurring 14 ± 2.4 days following hCG administration.
The mean hospitalization period during the OHSS epi-
sode was 7.2 ± 3.4 days. All the five OHSS patients pre-
sented with ascites and with mean hematocrit levels of
43.8 ± 3.0%. One patient had pleural effusion and two
others suffered from oliguria. During hospitalization, all
patients underwent careful and frequent evaluation and
strict monitoring of fluid intake and urine output. IV fluid
(crystalloids and colloids) were administered when appro-
priate. Three patients underwent ultrasound-guided para-
centesis of ascitic fluid.
Interleukin-2 and SOCS-1 mRNA levels are pre-
sented in Table 1 and Figure 2. While IL-2 mRNA
levels in PBMCs were significantly higher in the OHSS
as compared to the control groups (2.449 ± 0.255 vs
1.043 ± 0.146; p < 0.01, respectively), SOCS-1 mRNA
levels were non-significantly lower (0.541 ± 0.144 vs
1.171 ± 0.423; p = 0.22, respectively). Moreover, the
ratio between IL-2 and SOCS-1 mRNA levels, was
significantly higher in the OHSS as compared to the
control group (5.856 vs 1.943; p < 0.04, respectively).
Table 1 Demographic and clinical characteristics of the study groups
OHSS(5) CONTROL(5) P value
Age (years) Mean + SE 32.6 ± 2.3 36.6 ± 5.8 ns
Median (range) 33 (30–36) 38 (27–41)
Parity Mean + SE 0.8 ± 1.3 0.6 ± 0.5 ns
Median (range) 0 (1–3) 1 (0–1)
BMI (Kg/m2) Mean + SE 24.2 ± 5.7 24.5 ± 5.6 ns
Median (range) 24.9 (16.6-32.4) 22.5 (19.7-34.7)
Cause of infertility: ns
PCO (%) 1(20) 1 (20)
Mechanical (%) 1(20) 0 (0)
Male factor (%) 2(40) 3 (60)
Unexplained (%) 1(20) 1 (20)
Serum estradiol level on day of hCG administration (pmol/L) Mean + SE 9292 ± 2464 4167 ± 2730 <0.02
Median (range) 9336 (6589–11908) 3645 (1153–8575)
Number of oocytes retrieved Mean + SE 15.8 ± 2.3 7.8 ± 3.9 <0.002
Median (range) 16 (12–18) 9 (2–12)
IL-2 mRNA levels Mean + SE 2.449 ± 0.255 1.043 ± 0.146 <0.01
Median (range) 2.272 (1.915-3.403) 1.0 (0.6-1.59)
SOCS-1 mRNA levels Mean + SE 0.541 ± 0.144 1.171 ± 0.423 0.22
Median (range) 0.425 (0.225-0.974) 1.0 (0.285-2.821)
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In the present preliminary study, we have demonstrated
for the first time, a significantly higher IL-2 mRNA ex-
pression in PBMCs of OHSS patients as compared to
normal controls. Moreover, the IL-2 to SOCS-1 mRNA
expression ratio was also significantly increased, indicat-
ing a trend toward T cell activation [12] as a possible
culprit to VLS/OHSS.
Together with the accumulating evidence concern-
ing the interaction between the immune and repro-
ductive systems that results from sharing certain
lymphohematopoietic cytokines and their receptors
[13], several cytokines have been proposed as the inter-
mediate, released by gonadotropin-hyperstimulated
ovaries at ovulation, which causes the increased in
capillary permeability [3]. However, despite many
years of clinical experience, no significant evidence
exists to prove neither absolute nor ultimate role of
these inflammatory mediators in the pathophysiology
of OHSS [3].
Since, OHSS almost always develops after hCG ad-
ministration or in early pregnancy, it was suggested
that the hyperstimulated human ovaries produce and
secrete factor(s) that cause OHSS, probably by activat-
ing a systemic inflammatory response [3,14]. This
notion was based on the similarity of VLS to the clin-
ical picture of OHSS [3,15], the significantly highercytokine concentration in the follicular fluid at the
time of oocyte retrieval in patients in whom OHSS
subsequently developed [4,14,16], and the neutrophil
and endothelial activations following hCG administra-
tion [17-19].
This hypothesis was further substantiated by the ob-
served dose–response modulation of IL-2 production
by hCG in short-term primary culture of granulosa
cell derived from patients undergoing controlled ovar-
ian hyperstimulation (COH) [20]. While, on the other
hand, in vitro studies have demonstrated a negative ef-
fect of hCG on PBMCs IL-2 production in normal
healthy volunteers [21], or women undergoing COH
for IVF without OHSS [22]. This later observations
are in line with the growing evidence that hCG may
act directly as an immune modulator [23] through its
widely distributed receptors in nongonadal tissue, in-
cluding immune cells, and the observed improvement
of symptoms in patients with a Th1-dependent auto-
immune disease, during pregnancy [24]. Moreover,
animal studies confirmed the immunomodulatory ef-
fect of hCG, by downregulating effector cells, including
Th1 cells, and suppressing interferon-gamma produc-
tion [25].
While the aforementioned finding provide support
for a modulatory role of hCG in the immune response








































Figure 2 PBMCs IL-2 and SOCS-1 mRNA levels in the OHSS and control groups.
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hCG, according to our present preliminary findings,
the presence of hCG apparently might play a causative
role in OHSS, probably by inhibiting SOCS-1 mRNA
expression and leading to IL-2 dominance with the
consequent activation of the inflammatory response.
Alternatively, despite the small sample size and the
inherent disadvantages of this pilot exploratory case
series, we observed a different IL-2 to SOCS-1 mRNA
expression ratio in PBMCs of patients suffering from
severe OHSS, as compared to normal pregnant women
without OHSS. This different or aberrant inflammatory
response to hCG, observed in OHSS patients, might
reflect a tendency toward immune system activation,
rather than suppression by hCG, in this particular
group of patients.Conclusion
Taken together, these data suggest that the normal
negative effect of hCG on PBMCs IL-2 production is
lost in women that developed OHSS and the resulting
dysregulation of IL2 expression and SOCS activation,
might be the culprit of OHSS.
We may therefore hypothesize that patients at risk to
develop OHSS possess an inherited paradoxical im-
mune response to hCG, with IL-2 instead of SOCS-1
dominance, leading to systemic inflammatory response
with the consequent development of OHSS/VLS.
Additional large prospective studies are required to
elucidate the effect of hCG on patients’ inherited in-
flammatory cascades, which may help discriminating
those at risk to develop severe OHSS from those who
are not.
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